Sara López-Tarruella Selected Research

Sara López-Tarruella Research Topics

Disease

17	Breast Neoplasms (Breast Cancer) 01/2022 - 10/2005
10	Neoplasms (Cancer) 01/2022 - 01/2009
5	Triple Negative Breast Neoplasms 12/2018 - 01/2016
2	Disease Progression 09/2021 - 10/2005
2	Circulating Neoplastic Cells 09/2021 - 01/2013
2	Pathologic Complete Response 12/2018 - 02/2017
1	Residual Neoplasm 01/2022
1	Dihydropyrimidine Dehydrogenase Deficiency 08/2021
1	Melanoma (Melanoma, Malignant) 10/2020
1	Renal Cell Carcinoma (Grawitz Tumor) 10/2020
1	Necrosis 10/2020
1	Neoplasm Metastasis (Metastasis) 12/2019
1	Xeroderma Pigmentosum (Kaposi's Disease) 10/2016
1	Ovarian Epithelial Carcinoma 02/2011
1	Ovarian Neoplasms (Ovarian Cancer) 02/2011
1	Pancreatic Neoplasms (Pancreatic Cancer) 06/2009
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2008
1	Neoplasm Micrometastasis 09/2006
1	Colorectal Neoplasms (Colorectal Cancer) 09/2006

Drug/Important Bio-Agent (IBA)

5	Pharmaceutical PreparationsIBA 12/2019 - 01/2009
4	Hormones (Hormone)IBA 01/2022 - 10/2016
4	PlatinumIBA 12/2018 - 02/2011
3	DNA (Deoxyribonucleic Acid)IBA 09/2021 - 01/2016
3	Carboplatin (JM8)FDA LinkGeneric 12/2018 - 02/2017
3	Docetaxel (Taxotere)FDA Link 12/2018 - 02/2017
2	Biological ProductsIBA 09/2021 - 01/2009
2	Circulating Tumor DNAIBA 09/2021 - 12/2019
2	Biomarkers (Surrogate Marker)IBA 12/2019 - 01/2009
2	taxaneIBA 12/2018 - 02/2017
2	AnthracyclinesIBA 12/2018 - 02/2017
2	neratinibIBA 01/2017 - 06/2012
2	Trastuzumab (Herceptin)FDA Link 01/2016 - 10/2005
1	BO-112IBA 10/2020
1	pembrolizumabIBA 10/2020
1	NivolumabIBA 10/2020
1	Poly I-CIBA 10/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 02/2020
1	talazoparibIBA 02/2020
1	olaparibIBA 02/2020
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 02/2020
1	Capecitabine (Xeloda)FDA Link 01/2018
1	ribociclibIBA 10/2017
1	Phenobarbital (Luminal)FDA Link 10/2017
1	Messenger RNA (mRNA)IBA 10/2016
1	human ERBB2 proteinIBA 10/2016
1	TrabectedinIBA 10/2016
1	Immune Checkpoint InhibitorsIBA 01/2016
1	abemaciclibIBA 01/2016
1	Tyrosine Kinase InhibitorsIBA 01/2016
1	VaccinesIBA 01/2016
1	Lapatinib (GW572016)FDA Link 01/2016
1	Immunoconjugates (Immunoconjugate)IBA 01/2016
1	palbociclibIBA 01/2016
1	pertuzumabIBA 01/2016
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2016
1	Taxoids (Taxanes)IBA 07/2015
1	Drug CombinationsIBA 06/2012
1	Antineoplastic Agents (Antineoplastics)IBA 06/2010
1	Phosphotransferases (Kinase)IBA 06/2010
1	Gemcitabine FDA Link 06/2009
1	AntibodiesIBA 09/2006
1	thiamine triphosphorate (TTP)IBA 10/2005

Therapy/Procedure

9	Therapeutics 12/2019 - 10/2005
6	Drug Therapy (Chemotherapy) 08/2021 - 01/2009
5	Neoadjuvant Therapy 01/2022 - 01/2016
2	Radiotherapy 09/2015 - 01/2008
2	Adjuvant Chemotherapy 02/2011 - 01/2009
1	Intravenous Infusions 10/2016
1	Aftercare (After-Treatment) 09/2015
1	Maintenance Chemotherapy 07/2013
1	Induction Chemotherapy 01/2008